Arrhythmias are a potentially life-threatening complication of coronavirus 2019 (COVID-19) infection, with one study showing arrhythmias in 17% of non-intensive care unit (ICU) hospitalized patients and upwards of 44% of ICU patients . Currently, the mechanisms behind COVID-19’s impact on the heart are not well established. COVID-19 is thought to induce the upregulation of angiotensin-converting enzyme (ACE)-2 receptors in various organs which the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can use as an entry point.
Tagged: Journal of Cardiology
Peripheral arterial disease (PAD) is a phenotype of atherosclerotic disease that results in intermittent claudication during walking, as well as resting pain, skin ulcers, and gangrene. The prevalence of PAD continues to increase with smoking, diabetes mellitus, hypertension, and obesity. Recent meta-analyses have estimated over 200 million people worldwide to be affected, including in Asian countries.[1,2] In the REACH registry,[3,4] patients with coronary artery disease, cerebrovascular disease, lower limb PAD, and three or more risk factors for arteriosclerosis or thrombotic disease were enrolled, and their prognoses were examined.
Predictive value of aspartate aminotransferase-to-alanine aminotransferase ratio for contrast-associated acute kidney injury in patients undergoing elective percutaneous coronary intervention
Contrast-associated acute kidney injury (CA-AKI) is related to the intravascular administration of contrast agents and is the major complication after percutaneous coronary intervention (PCI). As a third leading cause of AKI , CA-AKI is a major contributor to prolonged hospitalization, persistent renal injury, dialysis, and increased risk of mortality [2–4]. Because of the harmfulness and preventability of CA-AKI, preoperative identification of patients at high risk and adequate prophylactic measures are of paramount importance.
Various models for long-term mortality prediction following acute coronary syndrome (ACS) have been developed over the past two decades, mostly using regression-based models. The recent european society of cardiology (ESC) NSTE-ACS guidelines  downgraded their recommendation of use of GRACE score from class I to class IIa based on level B evidence, likely as a recognition of the need for more research and development of more sophisticated clinical risk scores.
Echocardiography in the diagnostic evaluation and phenotyping of heart failure with preserved ejection fraction
Heart failure (HF) with preserved ejection fraction (HFpEF) is the dominant form of HF, and its prevalence relative to HF with reduced ejection fraction (HFrEF) has been growing due to the aging of the general population and the increasing burden of metabolic comorbidities, such as systemic hypertension, diabetes mellitus (DM), and obesity [1–5]. Rather than being characterized by an isolated abnormality in left ventricular (LV) diastolic function, it is now evident that HFpEF is a heterogeneous syndrome that has multiple cardiac, vascular, and peripheral limitations [6,7].